Cell engineering and immunotherapy research are key approaches to the future of cancer treatment. The Center for Cell Engineering plays an integral role in this research, providing and developing the tools needed by investigators and clinicians to conduct innovative clinical trials.
The Center for Cell Engineering focuses on two major areas: immune engineering with a focus on T lymphocytes, dendritic cells, natural killer cells and artificial antigen presenting cells to stimulate the body's immune response to cancer, and human stem cell research, with a dual focus on hematologic and neurologic disorders.
Below are some of the current protocols:
Clinical Investigation
| Project | Investigator(s) |
|---|---|
| A Phase I Dose-Escalation Trial for Donor T Cells Sensitized with Pentadecapeptides of the CMV-PP65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants | Richard J. O'Reilly, MD Guenther Koehne, MD, PhD |
| A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | Renier J. Brentjens, MD, PhD Isabelle Rivière, PhD Michel Sadelain, MD, PhD David A. Scheinberg, MD, PhD |
| Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant | Katharine C. Hsu, MD, PhD James Young, MD Ann Jakubowski, MD, PhD Miguel-Angel Perales, MD James Young, MD |
| A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | Marco Davila, MD, PhD Renier Brentjens, MD, PhD Isabelle Riviere, PhD |
| Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) | Susan Slovin, MD, PhD Renier Brentjens, MD, PhD Vladimir Ponomarev, PhD Riviere, Isabelle, PhD Sadelain, Michel, MD, PhD Howard Scher, MD Heiko Schoder, MD |
| A Phase I Dose Escalation Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the B-Cell Specific Antigen CD19 Positive Residual Or Relapsed Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | Nancy Kernan, MD Renier Brentjens, MD, PhD Isabelle Riviere, PhD |
| A Phase I Trial of Consolidation Therapy with Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients with Chronic Lymphocytic Leukemia Following Upfront Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab | Jae Park, MD Renier Brentjens, MD, PhD Nicole Lamanna, MD Isabelle Riviere, PhD |
| Pilot Trial of Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant | Heather Landau, MD Sergio Giralt, MD |
| A Phase II Study of The Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From A Normal HLA- Compatible Or Partially- Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies. | Richard O'Reilly, MD Ekaterina Doubrovina, MD Nancy Kernan, MD Esperanza Papadopoulos, MD Susan Prockop, MD |
